Navigation Links
Curbing world's most fatal diseases: consensus created by health experts offers global prescription
Date:11/21/2007

Several of the worlds most eminent health scientists and organizations today publish a landmark global consensus on the 20 foremost measures needed to curb humanitys most fatal diseases, their study featured in Nature magazine.

Known as chronic, non-communicable diseases, they are reaching world epidemic proportions and include cardiovascular diseases (mainly heart disease and stroke), several cancers, chronic respiratory conditions, and type 2 diabetes.

In their paper for Nature, the 19 authors (list appended) say chronic non-communicable diseases:

  • Cause the greatest share of death and disability worldwide;
  • Account for over 60% of deaths worldwide, four-fifths of those fatalities being citizens of low and middle income countries;
  • Cause twice as many deaths as the combined total of HIV/AIDS, tuberculosis, malaria, maternal and peri-natal conditions, and nutritional deficiencies.

Researchers used the structured consensus-building Delphi technique to create the Grand Challenges in Chronic Non-Communicable Diseases (CNCDs) a distillation of informed opinions drawn from 155 panel members across 50 nations, carefully selected from recommendations.

Study authors say the result is an authoritative list of the 20 most important challenges today to restraining and reversing the toll of these slow killer illnesses. The list of Grand Challenges is accompanied by research priorities for meeting them, drawn from the study data and finalized by 27 leading world health figures guiding the project (list appended).

CNCDs, defined by the WHO as cardio-vascular disease, type 2 diabetes, chronic respiratory diseases and certain cancers, are largely preventable. Its estimated that eliminating key risk factors (poor diet, physical inactivity, smoking) would prevent 80% of heart disease, strokes and type 2 diabetes, and over 40% of cancer cases.

The initiatives leaders say their goals are to galva
'/>"/>

Contact: Terry Collins
terrycollins@rogers.com
416-538-8712
Program on Life Sciences, Ethics and Policy,McLaughlin-Rotman Centre for Global Health  
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Early, routine testing for HIV is key to curbing the disease among teens
2. CHPA Commends Senator Biden on Legislation Aimed at Curbing Medicine-Abuse Trend
3. BODY WORLDS 2 & Breathe California Pair Up for Some Ash Kicking
4. New Kidney Disease Can Be Fatal
5. U of M performs first systemic therapy for fatal childhood disease
6. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
7. eHealth Initiative Releases Blueprint Representing Consensus on an Action Plan for Transforming U.S. Healthcare Using Health IT
8. Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain
9. Health Information Exchange Consensus Conference Reinforces Key Role of State-Level Entities
10. Not all risk is created equal
11. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Curbing world's most fatal diseases: consensus created by health experts offers global prescription
Curbing world's most fatal diseases: consensus created by health experts offers global prescription
Breaking Medicine Technology:Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Zyomyx Point of Care CD4 Test Selected by CD4 Initiative to Help Treat HIV AIDS Patients in Developing Countries 6315 1Zyomyx Point of Care CD4 Test Selected by CD4 Initiative to Help Treat HIV AIDS Patients in Developing Countries 6315 2Zyomyx Point of Care CD4 Test Selected by CD4 Initiative to Help Treat HIV AIDS Patients in Developing Countries 6315 3Mercy Health Plans Receives Five Star Excellent Rating 61479 1Mercy Health Plans Receives Five Star Excellent Rating 61479 2Vibrations key to efficiency of green fluorescent protein 14861 1Vibrations key to efficiency of green fluorescent protein 14861 2Vibrations key to efficiency of green fluorescent protein 14861 3Vibrations key to efficiency of green fluorescent protein 14861 4